1,2-Dimyristoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) | 185463-23-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 1,2-Dimyristoyl-sn-glycero-3-(phospho-rac-(1-glycerol))
• 英文别名: [(2R)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-tetradecanoyloxypropyl] tetradecanoate
• CAS: 185463-23-4
• 化学式: C₃₄H₆₇O₁₀P
• 分子量: 666.9
• InChiKey: BPHQZTVXXXJVHI-IADGFXSZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10
• 重原子数：
  45
• 可旋转键数：
  36
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  149
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
  申请人：Nammi Therapeutics, Inc.

  公开号：US20220080051A1

  公开（公告）日：2022-03-17

  Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising PD-1 Prodrugs and methods of making the nanocarriers are disclosed herein. The PD-1 Prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit PD-1-L1/L2. The PD-1 Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

  本文揭示了制备和/或共同制备的纳米载体（例如，LNPs和/或SLNPs），其中包括PD-1前药，以及制备这些纳米载体的方法。PD-1前药组合物包括药物基团、脂质基团和抑制PD-1-L1/L2的连接单元。这些PD-1前药可以被配制和/或共同配制到纳米载体中，从而提供一种利用靶向药物传递载体治疗癌症、免疫性疾病和其他疾病的方法。
• Nanoalum particles comprising a PAA sizing agent
  申请人：Infectious Disease Research Institute

  公开号：US11173126B2

  公开（公告）日：2021-11-16

  Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle ranges from about 1 nm to 450 nm. Such nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.

  本文提供的纳米铝颗粒由一种铝盐和一种施胶剂组成，其中颗粒的尺寸范围为约 1 纳米至 450 纳米。这种纳米铝颗粒是稳定的，可在装瓶前进行终端灭菌步骤。此外，还提供了包含纳米铝颗粒的组合物以及纳米铝颗粒的制造和使用方法。
• COMPOSITIONS AND METHODS FOR DELIVERY OF DOUBLE-STRANDED RNA
  申请人：Cui Kunyuan

  公开号：US20070293449A1

  公开（公告）日：2007-12-20

  Pharmaceutical compositions and methods of use of a composition containing a double-stranded RNA (dsRNA), cationic lipids, non-cationic lipids, and lipophilic delivery-enhancing compounds.
• COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY
  申请人：Cui Kunyuan

  公开号：US20070281900A1

  公开（公告）日：2007-12-06

  A composition of an interfering RNA comprising a double-stranded RNA (dsRNA) molecule having a double-stranded region of from about 15 to about 40 base pairs, a peptide having a hydrophobic region and a cationic region, and a non-cationic phospholipid, and uses thereof.
• LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
  申请人：Infectious Disease Research Institute

  公开号：US20200276299A1

  公开（公告）日：2020-09-03

  Provided herein are liposomal formulations containing saponin and optionally, a lipopolysaccharide. Also provided IC herein are pharmaceutical compositions and vaccine compositions comprising the liposomal formulations and an antigen. The pharmaceutical compositions and vaccine compositions are capable of eliciting or enhancing of an immune response, for example, for vaccine or therapeutic uses. Compositions and methods related to making the liposomal formulations and using the liposomal formulations for eliciting or enhancing an immune response are also provided.